PD-L1 positron emission tomography imaging in patients with non-small cell lung cancer: preliminary results of the ImmunoPETphase 0 study

Fiona Hegi-Johnson; Stacey E. Rudd; Christian W. Wichmann; Tim Akhurst; Peter Roselt; Sandra Sursock; Jenny Trinh; Thomas John; Lisa Devereux; Paul S. Donnelly; Rodney J. Hicks; Andrew M. Scott; Daniel Steinfort; Stephen Fox; Benjamin Blyth; Sagun Parakh; Gerard G. Hanna; Jason Callahan; Kate Burbury; Michael MacManus

doi:10.1016/j.ijrobp.2023.05.019

PD-L1 positron emission tomography imaging in patients with non-small cell lung cancer: preliminary results of the ImmunoPETphase 0 study

Fiona Hegi-Johnson^*, Stacey E. Rudd, Christian W. Wichmann, Tim Akhurst, Peter Roselt, Sandra Sursock, Jenny Trinh, Thomas John, Lisa Devereux, Paul S. Donnelly, Rodney J. Hicks, Andrew M. Scott, Daniel Steinfort, Stephen Fox, Benjamin Blyth, Sagun Parakh, Gerard G. Hanna, Jason Callahan, Kate Burbury, Michael MacManus

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Original language	English
Pages (from-to)	675-682
Number of pages	8
Journal	International Journal of Radiation Oncology Biology Physics
Volume	117
Issue number	3
Early online date	03 Jul 2023
DOIs	https://doi.org/10.1016/j.ijrobp.2023.05.019
Publication status	Published - 01 Nov 2023
Externally published	Yes

Bibliographical note

Funding Information:
This is an investigator-initiated study sponsored by the Peter MacCallum Cancer Center. This work was supported by AstraZeneca (grant number ESR-18-14346 ). The durvalumab and DFO-squaramide chelator were provided pro bono by AstraZeneca and Telix, respectively.

Funding Information:
Disclosures: F.H.-J. has clinical trial funding, has received honoraria, and has participated in advisory boards for AstraZeneca. She has received payments and honoraria from BeiGene and Merck Sharpe and Dohme (MSD) for lectures and presentations. Her work is supported by the Peter Mac Foundation and the Victorian Cancer Agency. S.E.R. and P.S.D. are inventors on intellectual property relating to the use of DFOSq that have been licensed from the University of Melbourne to Telix Pharmaceuticals. T.J. has received payments and honoraria from Bristol Myers Squibb (BMS) and AstraZeneca for lectures and presentations and sits on data safety and monitoring boards or advisory boards for Roche, BMS, AstraZeneca, Novartis, Amgen, Puma, MSD, and Merck. R.J.H. is a shareholder in Telix Pharmaceuticals and PreMIT Pty Ltd and on advisory boards for Telix and Revela. A.M.S. has received funding for research and clinical trials from AstraZeneca, ImaginAb, Telix, Medimmune, EMD Serono, Isotopen Technologien Munich (ITM), Fusion, Cyclotek, Curis, and AdAlta; is on advisory boards for Imagion and ImmunOs; and is an National Health and Medical Research Council (NHMRC) Investigator. S.F. has received payments and honoraria from AstraZeneca, Roche, Amgen, Novartis, Bayer, Glaxo Smith Kline (GSK), BMS, MSD, and Janssen for lectures and presentations. K.B. has received payments and honoraria from Bayer and Abbvie for lectures and presentations and participates on data safety and monitoring boards for Novartis. M.M.M. has received clinical trial funding from Varian Medical and is an NHMRC Grant Investigator.

ASJC Scopus subject areas

Radiation
Oncology
Radiology Nuclear Medicine and imaging
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ijrobp.2023.05.019Licence: Unspecified

Cite this

Hegi-Johnson, F., Rudd, S. E., Wichmann, C. W., Akhurst, T., Roselt, P., Sursock, S., Trinh, J., John, T., Devereux, L., Donnelly, P. S., Hicks, R. J., Scott, A. M., Steinfort, D., Fox, S., Blyth, B., Parakh, S., Hanna, G. G., Callahan, J., Burbury, K., & MacManus, M. (2023). PD-L1 positron emission tomography imaging in patients with non-small cell lung cancer: preliminary results of the ImmunoPETphase 0 study. International Journal of Radiation Oncology Biology Physics, 117(3), 675-682. https://doi.org/10.1016/j.ijrobp.2023.05.019

@article{e877b077bfd54afb88ec3b4c2dd060b4,

title = "PD-L1 positron emission tomography imaging in patients with non-small cell lung cancer: preliminary results of the ImmunoPETphase 0 study",

author = "Fiona Hegi-Johnson and Rudd, {Stacey E.} and Wichmann, {Christian W.} and Tim Akhurst and Peter Roselt and Sandra Sursock and Jenny Trinh and Thomas John and Lisa Devereux and Donnelly, {Paul S.} and Hicks, {Rodney J.} and Scott, {Andrew M.} and Daniel Steinfort and Stephen Fox and Benjamin Blyth and Sagun Parakh and Hanna, {Gerard G.} and Jason Callahan and Kate Burbury and Michael MacManus",

note = "Funding Information: This is an investigator-initiated study sponsored by the Peter MacCallum Cancer Center. This work was supported by AstraZeneca (grant number ESR-18-14346 ). The durvalumab and DFO-squaramide chelator were provided pro bono by AstraZeneca and Telix, respectively. Funding Information: Disclosures: F.H.-J. has clinical trial funding, has received honoraria, and has participated in advisory boards for AstraZeneca. She has received payments and honoraria from BeiGene and Merck Sharpe and Dohme (MSD) for lectures and presentations. Her work is supported by the Peter Mac Foundation and the Victorian Cancer Agency. S.E.R. and P.S.D. are inventors on intellectual property relating to the use of DFOSq that have been licensed from the University of Melbourne to Telix Pharmaceuticals. T.J. has received payments and honoraria from Bristol Myers Squibb (BMS) and AstraZeneca for lectures and presentations and sits on data safety and monitoring boards or advisory boards for Roche, BMS, AstraZeneca, Novartis, Amgen, Puma, MSD, and Merck. R.J.H. is a shareholder in Telix Pharmaceuticals and PreMIT Pty Ltd and on advisory boards for Telix and Revela. A.M.S. has received funding for research and clinical trials from AstraZeneca, ImaginAb, Telix, Medimmune, EMD Serono, Isotopen Technologien Munich (ITM), Fusion, Cyclotek, Curis, and AdAlta; is on advisory boards for Imagion and ImmunOs; and is an National Health and Medical Research Council (NHMRC) Investigator. S.F. has received payments and honoraria from AstraZeneca, Roche, Amgen, Novartis, Bayer, Glaxo Smith Kline (GSK), BMS, MSD, and Janssen for lectures and presentations. K.B. has received payments and honoraria from Bayer and Abbvie for lectures and presentations and participates on data safety and monitoring boards for Novartis. M.M.M. has received clinical trial funding from Varian Medical and is an NHMRC Grant Investigator. ",

year = "2023",

month = nov,

day = "1",

doi = "10.1016/j.ijrobp.2023.05.019",

language = "English",

volume = "117",

pages = "675--682",

journal = "International Journal of Radiation Oncology Biology Physics",

issn = "0360-3016",

publisher = "Elsevier Inc.",

number = "3",

}

Hegi-Johnson, F, Rudd, SE, Wichmann, CW, Akhurst, T, Roselt, P, Sursock, S, Trinh, J, John, T, Devereux, L, Donnelly, PS, Hicks, RJ, Scott, AM, Steinfort, D, Fox, S, Blyth, B, Parakh, S, Hanna, GG, Callahan, J, Burbury, K & MacManus, M 2023, 'PD-L1 positron emission tomography imaging in patients with non-small cell lung cancer: preliminary results of the ImmunoPETphase 0 study', International Journal of Radiation Oncology Biology Physics, vol. 117, no. 3, pp. 675-682. https://doi.org/10.1016/j.ijrobp.2023.05.019

PD-L1 positron emission tomography imaging in patients with non-small cell lung cancer: preliminary results of the ImmunoPETphase 0 study. / Hegi-Johnson, Fiona; Rudd, Stacey E.; Wichmann, Christian W. et al.
In: International Journal of Radiation Oncology Biology Physics, Vol. 117, No. 3, 01.11.2023, p. 675-682.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - PD-L1 positron emission tomography imaging in patients with non-small cell lung cancer: preliminary results of the ImmunoPETphase 0 study

AU - Hegi-Johnson, Fiona

AU - Rudd, Stacey E.

AU - Wichmann, Christian W.

AU - Akhurst, Tim

AU - Roselt, Peter

AU - Sursock, Sandra

AU - Trinh, Jenny

AU - John, Thomas

AU - Devereux, Lisa

AU - Donnelly, Paul S.

AU - Hicks, Rodney J.

AU - Scott, Andrew M.

AU - Steinfort, Daniel

AU - Fox, Stephen

AU - Blyth, Benjamin

AU - Parakh, Sagun

AU - Hanna, Gerard G.

AU - Callahan, Jason

AU - Burbury, Kate

AU - MacManus, Michael

N1 - Funding Information: This is an investigator-initiated study sponsored by the Peter MacCallum Cancer Center. This work was supported by AstraZeneca (grant number ESR-18-14346 ). The durvalumab and DFO-squaramide chelator were provided pro bono by AstraZeneca and Telix, respectively. Funding Information: Disclosures: F.H.-J. has clinical trial funding, has received honoraria, and has participated in advisory boards for AstraZeneca. She has received payments and honoraria from BeiGene and Merck Sharpe and Dohme (MSD) for lectures and presentations. Her work is supported by the Peter Mac Foundation and the Victorian Cancer Agency. S.E.R. and P.S.D. are inventors on intellectual property relating to the use of DFOSq that have been licensed from the University of Melbourne to Telix Pharmaceuticals. T.J. has received payments and honoraria from Bristol Myers Squibb (BMS) and AstraZeneca for lectures and presentations and sits on data safety and monitoring boards or advisory boards for Roche, BMS, AstraZeneca, Novartis, Amgen, Puma, MSD, and Merck. R.J.H. is a shareholder in Telix Pharmaceuticals and PreMIT Pty Ltd and on advisory boards for Telix and Revela. A.M.S. has received funding for research and clinical trials from AstraZeneca, ImaginAb, Telix, Medimmune, EMD Serono, Isotopen Technologien Munich (ITM), Fusion, Cyclotek, Curis, and AdAlta; is on advisory boards for Imagion and ImmunOs; and is an National Health and Medical Research Council (NHMRC) Investigator. S.F. has received payments and honoraria from AstraZeneca, Roche, Amgen, Novartis, Bayer, Glaxo Smith Kline (GSK), BMS, MSD, and Janssen for lectures and presentations. K.B. has received payments and honoraria from Bayer and Abbvie for lectures and presentations and participates on data safety and monitoring boards for Novartis. M.M.M. has received clinical trial funding from Varian Medical and is an NHMRC Grant Investigator.

PY - 2023/11/1

Y1 - 2023/11/1

U2 - 10.1016/j.ijrobp.2023.05.019

DO - 10.1016/j.ijrobp.2023.05.019

M3 - Article

C2 - 37406824

AN - SCOPUS:85167979722

SN - 0360-3016

VL - 117

SP - 675

EP - 682

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

IS - 3

ER -